Naporafenib not checked

Erasca · Novartis Pharmaceuticals · ERAS-254 · LXH254

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
7 in total · 4 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-rafenib: Raf kinase inhibitors WHO name stem
How it’s given
“Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor”In the company’s words, NCT05907304 on ClinicalTrials.gov
Tested for
Advanced or Metastatic NRAS-mutant Melanoma, Melanoma, Advanced or Metastatic Solid Tumors, EGFR-mutant Non-small Cell Lung Cancer
Main trialPhase 3
“Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).”In the company’s words, NCT06346067 on ClinicalTrials.gov
Other names
ERAS-254 · LXH254

Other drugs for Advanced or Metastatic NRAS-mutant Melanoma

All 195 drugs for Advanced or Metastatic NRAS-mutant Melanoma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Apr 2028 A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Phase 2Active, not recruiting 2 Feb 2027 Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Phase 1Active, not recruiting 1 Jul 2025 A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Phase 1Active, not recruiting 12 Jul 2027 Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Phase 1Terminated 18 Feb 2022 Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Phase 1Terminated 24 Apr 2024 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Phase 1Terminated 25 Sep 2024 A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Naporafenib

Following is part of Solo: you see every change to Naporafenib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in